216 related articles for article (PubMed ID: 22596349)
1. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
Tang Y; Hamed HA; Poklepovic A; Dai Y; Grant S; Dent P
Mol Pharmacol; 2012 Aug; 82(2):322-32. PubMed ID: 22596349
[TBL] [Abstract][Full Text] [Related]
2. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.
Mitchell C; Park M; Eulitt P; Yang C; Yacoub A; Dent P
Mol Pharmacol; 2010 Nov; 78(5):909-17. PubMed ID: 20696794
[TBL] [Abstract][Full Text] [Related]
3. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.
Booth L; Cruickshanks N; Ridder T; Dai Y; Grant S; Dent P
Cancer Biol Ther; 2013 May; 14(5):458-65. PubMed ID: 23917378
[TBL] [Abstract][Full Text] [Related]
4. Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
Shibata H; Miuma S; Saldivar JC; Huebner K
Cancer Sci; 2011 Oct; 102(10):1882-8. PubMed ID: 21707865
[TBL] [Abstract][Full Text] [Related]
5. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation.
Min W; Bruhn C; Grigaravicius P; Zhou ZW; Li F; Krüger A; Siddeek B; Greulich KO; Popp O; Meisezahl C; Calkhoven CF; Bürkle A; Xu X; Wang ZQ
Nat Commun; 2013; 4():2993. PubMed ID: 24356582
[TBL] [Abstract][Full Text] [Related]
7. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
Booth L; Roberts J; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):786-796. PubMed ID: 30024813
[TBL] [Abstract][Full Text] [Related]
8. Enhancing CHK1 inhibitor lethality in glioblastoma.
Tang Y; Dai Y; Grant S; Dent P
Cancer Biol Ther; 2012 Apr; 13(6):379-88. PubMed ID: 22313687
[TBL] [Abstract][Full Text] [Related]
9. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
[TBL] [Abstract][Full Text] [Related]
10. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
[TBL] [Abstract][Full Text] [Related]
12. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
[TBL] [Abstract][Full Text] [Related]
13. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
Patel AG; Flatten KS; Schneider PA; Dai NT; McDonald JS; Poirier GG; Kaufmann SH
J Biol Chem; 2012 Feb; 287(6):4198-210. PubMed ID: 22158865
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.
Mitchell C; Hamed HA; Cruickshanks N; Tang Y; Bareford MD; Hubbard N; Tye G; Yacoub A; Dai Y; Grant S; Dent P
Cancer Biol Ther; 2011 Aug; 12(3):215-28. PubMed ID: 21642769
[TBL] [Abstract][Full Text] [Related]
15. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
Walton MI; Eve PD; Hayes A; Valenti M; De Haven Brandon A; Box G; Boxall KJ; Aherne GW; Eccles SA; Raynaud FI; Williams DH; Reader JC; Collins I; Garrett MD
Mol Cancer Ther; 2010 Jan; 9(1):89-100. PubMed ID: 20053762
[TBL] [Abstract][Full Text] [Related]
16. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.
Shen Y; Rehman FL; Feng Y; Boshuizen J; Bajrami I; Elliott R; Wang B; Lord CJ; Post LE; Ashworth A
Clin Cancer Res; 2013 Sep; 19(18):5003-15. PubMed ID: 23881923
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
Chen WH; Song SS; Qi MH; Huan XJ; Wang YQ; Jiang H; Ding J; Ren GB; Miao ZH; Li J
Acta Pharmacol Sin; 2017 Nov; 38(11):1521-1532. PubMed ID: 28770827
[TBL] [Abstract][Full Text] [Related]
19. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
Chornenkyy Y; Agnihotri S; Yu M; Buczkowicz P; Rakopoulos P; Golbourn B; Garzia L; Siddaway R; Leung S; Rutka JT; Taylor MD; Dirks PB; Hawkins C
Mol Cancer Ther; 2015 Nov; 14(11):2560-8. PubMed ID: 26351319
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.
Wang Z; Grosskurth SE; Cheung T; Petteruti P; Zhang J; Wang X; Wang W; Gharahdaghi F; Wu J; Su N; Howard RT; Mayo M; Widzowski D; Scott DA; Johannes JW; Lamb ML; Lawson D; Dry JR; Lyne PD; Tate EW; Zinda M; Mikule K; Fawell SE; Reimer C; Chen H
Cancer Res; 2018 Dec; 78(23):6691-6702. PubMed ID: 30297535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
